Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$9.77 - $21.47 $195,888 - $430,473
20,050 Added 51.48%
58,997 $868,000
Q4 2023

Feb 14, 2024

BUY
$4.48 - $10.11 $124,073 - $279,996
27,695 Added 246.13%
38,947 $374,000
Q3 2023

Nov 14, 2023

SELL
$4.48 - $6.19 $106,668 - $147,383
-23,810 Reduced 67.91%
11,252 $52,000
Q2 2023

Aug 14, 2023

BUY
$4.62 - $7.54 $161,986 - $264,367
35,062 New
35,062 $187,000
Q4 2022

Feb 14, 2023

SELL
$5.62 - $6.98 $19,209 - $23,857
-3,418 Reduced 12.82%
23,244 $155,000
Q3 2022

Nov 14, 2022

SELL
$3.01 - $5.22 $25,094 - $43,519
-8,337 Reduced 23.82%
26,662 $92,000
Q2 2022

Aug 15, 2022

BUY
$2.25 - $9.99 $78,747 - $349,640
34,999 New
34,999 $103,000
Q2 2021

Aug 16, 2021

SELL
$20.49 - $35.63 $2.62 Million - $4.56 Million
-127,866 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$18.99 - $33.2 $2.43 Million - $4.25 Million
127,866 New
127,866 $4.07 Million
Q4 2020

Feb 16, 2021

SELL
$19.41 - $26.0 $1.54 Million - $2.07 Million
-79,563 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$24.69 - $31.6 $1.96 Million - $2.51 Million
79,563 New
79,563 $2 Million
Q3 2019

Nov 14, 2019

SELL
$12.44 - $17.48 $911,988 - $1.28 Million
-73,311 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$14.51 - $19.71 $1.06 Million - $1.44 Million
73,311 New
73,311 $1.24 Million
Q3 2018

Nov 14, 2018

SELL
$19.26 - $23.46 $380,808 - $463,851
-19,772 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$19.78 - $24.67 $391,090 - $487,775
19,772 New
19,772 $408,000

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $208M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Balyasny Asset Management LLC Portfolio

Follow Balyasny Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.